|
|
||||||||
The Journal of Immunology, Vol 153, Issue 1 325-332, Copyright © 1994 by American Association of Immunologists
ARTICLES |
CK Oh and DD Metcalfe
Allergic Diseases Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
TCA3 is a pro-inflammatory cytokine expressed in mast cells after activation. To examine how this gene is regulated, TCA3 mRNA levels were examined and nuclear run-on experiments and promoter analysis were performed. Northern blot analysis showed that TCA3 message appeared in mast cells within 2 h after induction, with a t1/2 of 30 min. Nuclear run-on experiments revealed that the appearance of TCA3 mRNA occurred in large part because of an increase in the level of de novo transcription. Analysis of the promoter region demonstrated that inducible gene expression was directed by a region extending between 1.324 kb and 0.082 kb upstream from the transcription start site. There was a 60- to 80-fold induction with TCA3 CAT constructs extending between 1.324 kb and 0.324 kb upstream from the transcription start site after treatment with PMA/A23187 and a 30- to 40-fold induction with Fc epsilon RI cross-linking. There was a seven- to eightfold induction with the region extending between 0.136 kb and 0.082 kb upstream from the transcription start site. TCA3 CAT constructs containing regions encompassing either the 0.042 kb or 2.0 kb sequence from the transcription start site were not able to direct CAT-protein synthesis. The TCA3 5' flanking sequence contained negative regulatory activity. Electrophoretic mobility shift assays revealed that protein in nuclear extracts of activated mast cells bound to an NF-kappa B element of the TCA3 gene. These findings demonstrate that the TCA3 gene is regulated transcriptionally in mast cells, with minimal promoter sequences contained within the 0.082 kb upstream region of the TCA3 gene; a putative enhancer NF-kappa B element is contained between 0.324 kb and 0.136 kb and a putative inhibitory element is contained between 1.324 kb and 2.0 kb upstream from the transcription start site.
This article has been cited by other articles:
![]() |
S. H. Cho, C. H. Ryu, and C. K. Oh Plasminogen Activator Inhibitor-1 in the Pathogenesis of Asthma Experimental Biology and Medicine, February 1, 2004; 229(2): 138 - 146. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nakajima, N. Inagaki, H. Tanaka, A. Tanaka, M. Yoshikawa, M. Tamari, K. Hasegawa, K. Matsumoto, H. Tachimoto, M. Ebisawa, et al. Marked increase in CC chemokine gene expression in both human and mouse mast cell transcriptomes following Fcepsilon receptor I cross-linking: an interspecies comparison Blood, December 1, 2002; 100(12): 3861 - 3868. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ruckes, D. Saul, J. Van Snick, O. Hermine, and R. Grassmann Autocrine antiapoptotic stimulation of cultured adult T-cell leukemia cells by overexpression of the chemokine I-309 Blood, August 15, 2001; 98(4): 1150 - 1159. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. K. Oh, S. G. Filler, and S. H. Cho Eukaryotic Translation Initiation Factor-6 Enhances Histamine and IL-2 Production in Mast Cells J. Immunol., March 1, 2001; 166(5): 3606 - 3611. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. Pyatt, W. S. Stillman, Y. Yang, S. Gross, J. h. Zheng, and R. D. Irons An Essential Role for NF-{kappa}B in Human CD34+ Bone Marrow Cell Survival Blood, May 15, 1999; 93(10): 3302 - 3308. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Pelletier, N. Varin-Blank, J. Rivera, B. Iannascoli, F. Marchand, B. David, A. Weyer, and U. Blank Fc{epsilon}RI-Mediated Induction of TNF-{alpha} Gene Expression in the RBL-2H3 Mast Cell Line: Regulation by a Novel NF-{kappa}B-Like Nuclear Binding Complex J. Immunol., November 1, 1998; 161(9): 4768 - 4776. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |